Fulvestrant
- Generic Name
- Fulvestrant
- Brand Names
- Faslodex, Fulvestrant Mylan
- Drug Type
- Small Molecule
- Chemical Formula
- C32H47F5O3S
- CAS Number
- 129453-61-8
- Unique Ingredient Identifier
- 22X328QOC4
- Background
Fulvestrant is a drug treatment of hormone receptor (HR)-positive metastatic breast cancer in post-menopausal women with disease progression following anti-estrogen therapy. It is an estrogen receptor antagonist with no agonist effects, which works both by down-regulating and by degrading the estrogen receptor. While it is used as monotherapy for the treatme...
- Indication
For the treatment of hormone receptor positive metastatic breast cancer in postmenopausal women with disease progression following anti-estrogen therapy, as monotherapy or in combination with other antineoplastic agents.
- Associated Conditions
- Advanced Breast Cancer, Advanced or Metastatic Breast Cancer
- Associated Therapies
- -
A Study of E7090 as Monotherapy and in Combination With Other Anticancer Agents in Participants With Estrogen Receptor Positive (ER+) and Human Epidermal Growth Receptor 2 Negative (HER2-) Recurrent/Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-10-01
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 72
- Registration Number
- NCT04572295
- Locations
- 🇯🇵
Eisai Trial Site 10, Kitaadachi-gun, Saitama, Japan
🇯🇵Eisai Trial Site 2, Shinagawa-ku, Tokyo, Japan
🇯🇵Eisai Trial Site 6, Kashiwa, Chiba, Japan
DNA-Guided Second Line Adjuvant Therapy For High Residual Risk, Stage II-III, Hormone Receptor Positive, HER2 Negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-09-28
- Last Posted Date
- 2023-03-21
- Lead Sponsor
- Criterium, Inc.
- Target Recruit Count
- 100
- Registration Number
- NCT04567420
- Locations
- 🇺🇸
USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸University of Arizona Cancer Center, Tucson, Arizona, United States
🇺🇸University of Wisconsin Clinical Science Center, Madison, Wisconsin, United States
A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-09-21
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 138
- Registration Number
- NCT04556773
- Locations
- 🇨🇳
Research Site, Taoyuan, Taiwan
Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Chinese Men and Postmenopausal Women With Advanced Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-09-10
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 69
- Registration Number
- NCT04544189
- Locations
- 🇨🇳
Novartis Investigative Site, Tianjin, China
Patterns of Treatment and Outcome of Palbociclib Plus Endocrine Therapy
- Conditions
- Interventions
- First Posted Date
- 2020-08-24
- Last Posted Date
- 2020-08-24
- Lead Sponsor
- Istituti Clinici Scientifici Maugeri SpA
- Target Recruit Count
- 191
- Registration Number
- NCT04524728
- Locations
- 🇮🇹
Istituti Clinici Scientifici Maugeri IRCCS, Pavia, Italy
Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant in Japanese Men and Postmenopausal Women With Advanced Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-08-24
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 24
- Registration Number
- NCT04524000
- Locations
- 🇯🇵
Novartis Investigative Site, Niigata, Japan
Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic Cancer
- Conditions
- Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IIIA Breast Cancer AJCC v8Anatomic Stage IIIB Breast Cancer AJCC v8Anatomic Stage IIIC Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Hormone Receptor Positive Breast CarcinomaLocally Advanced Breast CarcinomaMetastatic Breast CarcinomaMetastatic Endometrioid AdenocarcinomaMetastatic Primary Peritoneal Carcinoma
- Interventions
- First Posted Date
- 2020-08-04
- Last Posted Date
- 2021-05-18
- Lead Sponsor
- Pamela Munster
- Registration Number
- NCT04498520
Impact of Endocrine Therapy and Abemaciclib on Host and Tumor Immune Cell Repertoire/Function in Advanced ER+/HER2- Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-04-20
- Last Posted Date
- 2024-02-14
- Lead Sponsor
- Duke University
- Target Recruit Count
- 18
- Registration Number
- NCT04352777
- Locations
- 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
Anti-HER2 Therapy + Fulvestrant/Capecitabine in Women With HR+, HER2+, Non-visceral Metastases Stage IV Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-04-08
- Last Posted Date
- 2020-04-08
- Target Recruit Count
- 493
- Registration Number
- NCT04337658
- Locations
- 🇨🇳
Second Affiliated Hospital, Zhejiang University, School of Medicine, Hangzhou, Zhejiang, China
🇨🇳Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Neo-Adjuvant Abemaciclib With Fulvestrant in Patients With ER/PR +HER Negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-03-12
- Last Posted Date
- 2023-06-06
- Lead Sponsor
- University of California, Irvine
- Target Recruit Count
- 1
- Registration Number
- NCT04305236
- Locations
- 🇺🇸
Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.